81 filings
Page 2 of 5
8-K
2lr unxaq
10 Aug 23
Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
7:00am
8-K
mra3nfv2qhpppqs
16 Jun 23
Submission of Matters to a Vote of Security Holders
9:02am
8-K
59bd25epuzq9h4b516al
15 Jun 23
Entry into a Material Definitive Agreement
6:37am
8-K
3yl2qxno w8dyrtp33wn
15 May 23
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
7:00am
ARS
u5olunswa0biaj
28 Apr 23
Annual report to shareholders
7:52am
DEFA14A
6vst6xbl jw4
28 Apr 23
Additional proxy soliciting materials
7:49am
S-8
90x2fg afx
2 Mar 23
Registration of securities for employees
7:50am
8-K
g0oh urwg28l
2 Mar 23
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
7:01am
8-K
cfl6jbxk2x4a bx9yizz
17 Feb 23
Amendments to Articles of Incorporation or Bylaws
6:31am
8-K
st6g6qcz
5 Dec 22
Other Events
6:47am
8-K
86tr6kzg5l
7 Nov 22
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
7:00am
S-3ASR
6c2l ku144gg
23 Sep 22
Automatic shelf registration
4:08pm
8-K
vfucjr0r36v7f6fa
9 Aug 22
Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
6:45am
8-K
lz1nt1ob4n
21 Jul 22
Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
4:46pm